文献速递心境障碍

新型脑渗透性HCN通道抑制剂的设计与验证:改善社会应激诱导的易感表型

Design and validation of novel brain-penetrant HCN channel inhibitors to ameliorate social stress-induced susceptible phenotype.
PubMed 文献 · Mol Psychiatry · 2025-04-08

该研究针对重度抑郁症(MDD)中脑腹侧被盖区(VTA)多巴胺信号异常及慢性社会挫败应激(CSDS)小鼠模型,设计并验证了西洛雷定(Cilobradine)类似物MS7710和MS7712。两种化合物对VTA多巴胺Ih电流的抑制效力与西洛雷定相似,但对VTA多巴胺放电频率的抑制更强,且脑/血浆浓度比更优;在更低剂量下即可抑制CSDS易感雄鼠VTA多巴胺神经元放电和爆发活动,MS7710在雌鼠中重复验证。单次腹腔注射MS7710可改善CSDS诱导的社会互动缺陷和奖赏相关认知不灵活性,持续至少两周。

要点

  • MS7710和MS7712对VTA多巴胺Ih电流的抑制效力与西洛雷定相似,但对放电频率的抑制更强。
  • MS7710和MS7712的脑/血浆浓度比优于西洛雷定,在更低剂量下抑制CSDS易感雄鼠VTA多巴胺神经元放电和爆发活动。
  • 单次腹腔注射MS7710可改善CSDS诱导的社会互动缺陷和奖赏相关认知不灵活性,持续至少两周。

核心结论

  • 研究鉴定出新型HCN通道抑制剂MS7710,具有改善的神经趋向性和应激缓解效应,可能为未来抗抑郁药物研发提供基础。

研究设计与样本

  • 临床前动物研究:在慢性社会挫败应激(CSDS)易感雄性和雌性小鼠中,比较西洛雷定类似物MS7710和MS7712与西洛雷定的神经趋向性和抑制效力。

主要发现

  • MS7710和MS7712对VTA多巴胺Ih电流的抑制效力与西洛雷定相似,对VTA多巴胺放电频率的抑制效力强于西洛雷定。
  • MS7710和MS7712的脑/血浆浓度比优于西洛雷定。
  • 在CSDS易感雄鼠中,MS7710和MS7712在比西洛雷定更低的剂量下即可抑制VTA多巴胺神经元放电频率和爆发活动;MS7710在CSDS易感雌鼠中重复验证。
  • 单次腹腔注射MS7710可改善CSDS诱导的社会互动缺陷和奖赏相关认知不灵活性,效果持续至少两周,见于雄性和雌性小鼠。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Major Depressive Disorder (MDD) is a devastating, multifactorial disease with limited pharmacological treatment options. Patients with MDD exhibit alterations in their dopamine (DA) signaling pathways through the midbrain ventral tegmental area (VTA). A similar observation is also detected in preclinical models of stress - mice exhibit behavioral and physiological impairments following chronic social defeat stress (CSDS). Prior studies demonstrate that CSDS-susceptible mice have increased VTA DA neuronal excitability, in part driven by an upregulation in hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels. Inhibiting HCN channels with known inhibitors such as Cilobradine alleviates the negative behavioral effects of CSDS. Here, we aimed to identify Cilobradine analogs with improved neural tropism and inhibitory efficacy. Two compounds, MS7710 and MS7712, differing by their left-hand side moieties, have a similar, potent inhibitory effect on VTA DA Ih currents as compared to Cilobradine, and a greater inhibitory effect than Cilobradine on VTA DA firing rate. We demonstrate that MS7710 and MS7712 have superior brain/plasma concentration ratios as compared to Cilobradine. They were efficacious at inhibiting VTA DA neuron firing rate and bursting activity in CSDS-susceptible male mice at lower doses than Cilobradine, which was recapitulated in female CSDS-susceptible mice with MS7710. Finally, we define that a single intraperitoneal injection of MS7710 ameliorates CSDS-induced social interaction deficits and reward-associated cognitive inflexibility for at least two weeks in male and female mice. These findings yield a novel HCN channel inhibitor with improved neural tropism and stress-alleviating effects that could provide a basis for future antidepressant drug discovery.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Teichman EM, Hu J, Lin HY, et al. Design and validation of novel brain-penetrant HCN channel inhibitors to ameliorate social stress-induced susceptible phenotype. Mol Psychiatry. 2025. PMID: 40199995. doi:10.1038/s41380-025-02972-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。